Skip to content
Dx

ICD-10-CM 2027 diagnosis code

D09.22Carcinoma in situ of left eye

✓ Billable / specific

D09.22 is a valid, billable ICD-10-CM code for carcinoma in situ of left eye. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Code unchanged since ICD-10-CM took effect on October 1, 2015. Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About D09.22

D09.22 is the ICD-10-CM diagnosis code for carcinoma in situ of left eye. It belongs to category D09 (carcinoma in situ of other and unspecified sites), block D00-D09 (in situ neoplasms) and chapter 2 (neoplasms). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within D09.2 (carcinoma in situ of eye), D09.22 is specifically for carcinoma in situ of left eye. Related codes cover unspecified eye (D09.20) and right eye (D09.21).

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 124 (Other Disorders of the Eye with MCC or Thrombolytic Agent, relative weight 1.2471) and DRG 125 (Other Disorders of the Eye without MCC, relative weight 0.7702), in MDC 02 (Diseases and Disorders of the Eye), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.

Before ICD-10, this condition was coded in ICD-9-CM as 234.0 (carcinoma in situ of eye).

Notes that apply from higher levels

Instructions written at a parent level also apply to D09.22.

› From D09.2 Carcinoma in situ of eye
Excludes1
  • carcinoma in situ of skin of eyelid (D04.1-)
› From D09 Carcinoma in situ of other and unspecified sites
Excludes1
  • melanoma in situ (D03.-)

Broader instructions also apply from D00-D09 In situ neoplasms and Chapter 2: Neoplasms.

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

ICD-9-CM equivalent

Converter →
  • 234.0Carcinoma in situ of eyeapproximate

From the CMS 2018 General Equivalence Mappings (GEMs), the final GEMs release.

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
  • No changes since FY2016.

Common questions about D09.22

Is D09.22 billable?

Yes. D09.22 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can D09.22 be used as a principal diagnosis?

Yes. The Medicare Code Editor doesn't restrict D09.22 as a principal diagnosis.

Is D09.22 a CC or MCC?

No. D09.22 is neither a CC nor an MCC under MS-DRG v44.0.

What DRG does D09.22 group to?

D09.22 is used in the MS-DRG v44.0 logic for MS-DRG 124 (Other Disorders of the Eye with MCC or Thrombolytic Agent) and MS-DRG 125 (Other Disorders of the Eye without MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.

What is the ICD-9 code for D09.22?

The CMS General Equivalence Mappings map D09.22 to ICD-9-CM 234.0.